Six year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic myeloid leukemia (CML) post interferon-a (IFN) Refractoriness/Intolerance.

被引：0
|
作者：
Kantarjian, Hagop M.
Sawyers, Charles
Hochhaus, Andreas
Schiffer, Charles A.
Guilhot, Francois
Niederwieser, Dietger W.
Gambacorti, Carlo
Stone, Richard M.
Fischer, Thomas
Goldman, John
Krahnke, T.
Mone, M.
Talpaz, Moshe
Druker, Brian J.
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Univ Heidelberg, D-6800 Mannheim, Germany
[4] Karmanos Canc Inst, Detroit, MI USA
[5] CHU La Miletrie, Poitiers, France
[6] Univ Leipzig, D-7010 Leipzig, Germany
[7] Inst Natl Tumori, Milan, Italy
[8] Dana Farber Canc Inst, Boston, MA USA
[9] Univ Mainz, D-6500 Mainz, Germany
[10] NHLBI, Bethesda, MD 20892 USA
[11] Univ Michigan, Ann Arbor, MI 48109 USA
[12] Oregon Hlth Sci Univ, Portland, OR 97201 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
428
引用
收藏
页码：130A / 131A
页数：2
相关论文
共 50 条
  • [1] Five year follow-up results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukemia (CML) treated with imatinib who are refractory/intolerant of interferon-α
    Gambacorti, C
    Talpaz, M
    Sawyers, CL
    Druker, BJ
    Hochhaus, A
    Schiffer, CA
    Guilhot, F
    Niederwieser, DW
    Stone, RM
    Goldman, JM
    Mone, M
    Krahnke, T
    Gathmann, I
    Kantarjian, HM
    BLOOD, 2005, 106 (11) : 317A - 317A
  • [2] Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Kantarjian, H.
    Giles, F.
    Bhalla, K.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Gallagher, N. J.
    Baccarani, M.
    leCoutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
    Kantarjian, Hagop M.
    Giles, Francis
    Bhalla, Kapil N.
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Haque, Ariful
    Gallagher, Neil J.
    Baccarani, Michele
    le Coutre, Philipp D.
    BLOOD, 2008, 112 (11) : 1112 - 1112
  • [4] Nilotinib in chronic myeloid leukaemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: follow-up results of a phase 2 study
    Clark, R.
    le Coutre, P.
    Giles, F. J.
    Hocchaus, A.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 40 - 40
  • [5] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
    Kantarjian, H.
    Giles, F. G.
    Bhalla, K. N. P.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Wang, J.
    Gallagher, N. J.
    Baccarani, M.
    Le Coutre, P. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 254 - 255
  • [6] Five-year follow-up results of imatinib 400 mg in late chronic phase chronic myeloid leukemia (CML) patients
    Iacobucci, I.
    Palandri, F.
    Amabile, M.
    Poerio, A.
    Soverini, S.
    Castagnetti, F.
    Testoni, N.
    Rosti, G.
    Baccarani, M.
    Martinelli, G.
    Palandri, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure
    Shan, J.
    O'Brien, S. M.
    Garcia-Manero, G.
    Faderl, S.
    Ravandi, F.
    Jabbour, E.
    Cortes, J. E.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials.
    Silver, RT
    Talpaz, M
    Sawyers, CL
    Druker, BJ
    Hochhaus, A
    Schiffer, CA
    Guilhot, F
    Goldman, JM
    Smith, BD
    Mone, M
    Kranhnke, T
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 11A - 11A
  • [9] Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Le Coutre, P. D.
    Giles, F.
    Hochhaus, A.
    Apperley, J. F.
    Ossenkoppele, G.
    Haque, A.
    Gallagher, N. J.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] SIX-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING DASATINIB
    Rea, D.
    Vellenga, E.
    Junghanss, C.
    Baccarani, M.
    Kantarjian, H.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 80 - 80
12345